person · Reporting owner

Chin Richard

Disclosed activity across 3 companies

Tapewire entity: 21194
SEC CIK: 0001337252

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cytek Biosciences, Inc.CTKB · Entity 5345	Director	August 18, 2026	August 20, 2026
SELLAS Life Sciences Group, Inc.GALE · Entity 4313	Director	October 10, 2017	October 10, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cytek Biosciences, Inc.

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,499	Reported balance After 2026-08-18 transaction · row 1 1 source row Row 1 · 2026-08-18 · Exercise / conversion · Acquired 6,107 · Balance 28,499 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	44,790	Reported balance After 2026-08-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-18 · Exercise / conversion · Disposed 6,107 · Balance 44,790 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter.

SELLAS Life Sciences Group, Inc.

Report date October 10, 2017 · Filed October 10, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	31,339	Reported balance After 2017-10-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-10-10 · Grant · Acquired 12,708 · Balance 31,339 F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.

F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kindred Biosciences, Inc.

Report date August 27, 2021 · Filed August 31, 2021

Section 16 reporting ended · disclosed 2021-08-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-08-27 transaction · row 1 1 source row Row 1 · 2021-08-27 · Disposition to issuer · Disposed 1,709,271 · Balance 0 F1: Represents 1,709,271 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share. Certain of these securities were restricted stock units ("RSUs") that represented the reporting person's right to receive the Kindred Biosciences, Inc.'s common stock. Pursuant to the Merger Agreement, the RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive a cash payment of $9.25 per share, subject to any required withholding of taxes.
Common StockSEC Table I · non-derivative	IndirectBy reporting person as custodian for son	Reported balance After 2021-08-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.
Common StockSEC Table I · non-derivative	IndirectBy reporting person as custodian for son	Reported balance After 2021-08-27 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.
Common StockSEC Table I · non-derivative	IndirectBy reporting person as custodian for daughter	Reported balance After 2021-08-27 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.
Common StockSEC Table I · non-derivative	IndirectBy reporting person as custodian for daughter	Reported balance After 2021-08-27 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2023-02-04	Direct	Reported balance After 2021-08-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-08-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2024-02-04	Direct	Reported balance After 2021-08-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-08-27 · Disposition to issuer · Disposed 350,000 · Balance 0 F4: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2025-02-05	Direct	Reported balance After 2021-08-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-08-27 · Disposition to issuer · Disposed 197,771 · Balance 0 F5: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2026-01-08	Direct	Reported balance After 2021-08-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-08-27 · Disposition to issuer · Disposed 197,771 · Balance 0 F6: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2027-01-23	Direct	Reported balance After 2021-08-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-08-27 · Disposition to issuer · Disposed 175,000 · Balance 0 F7: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75 · Expires 2028-01-22	Direct	Reported balance After 2021-08-27 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-08-27 · Disposition to issuer · Disposed 175,000 · Balance 0 F8: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-01-31	Direct	Reported balance After 2021-08-27 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-08-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F9: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.84 · Expires 2030-01-16	Direct	Reported balance After 2021-08-27 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-08-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F10: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19	Direct	Reported balance After 2021-08-27 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2021-08-27 · Disposition to issuer · Disposed 394,000 · Balance 0 F11: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 1,709,271 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share. Certain of these securities were restricted stock units ("RSUs") that represented the reporting person's right to receive the Kindred Biosciences, Inc.'s common stock. Pursuant to the Merger Agreement, the RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive a cash payment of $9.25 per share, subject to any required withholding of taxes.

F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.

F3: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

F4: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration.

F5: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

F6: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

F7: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

F8: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

F9: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

F10: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.

F11: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 18, 2026 Filed Aug 20, 2026 20:27 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	6,107	$0.00	$0.00	Disclosure SEC source: 0001337252-26-000005 · form4-08202026_080801.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,790 Underlying: Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter. F2 · derivative.expiration_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter. Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:27 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	6,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001337252-26-000005 · form4-08202026_080801.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 10, 2026 Filed Jun 12, 2026 23:27 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantDirector Stock Option (right to buy) · Derivative	18,261	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001337252-26-000003 · form4-06122026_110652.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,261 Underlying: Common Stock · 18,261 shares Expires 2036-06-10 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document
June 10, 2026 Filed Jun 12, 2026 23:27 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantRestricted Stock Units · Derivative	33,333	$0.00	$0.00	Disclosure SEC source: 0001337252-26-000003 · form4-06122026_110652.xml · derivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document
May 18, 2026 Filed May 20, 2026 21:59 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	6,107	$0.00	$0.00	Disclosure SEC source: 0001337252-26-000002 · form4-05202026_090523.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,897 Underlying: Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. Read SEC document
May 18, 2026 Filed May 20, 2026 21:59 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	6,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001337252-26-000002 · form4-05202026_090523.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:41 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	6,107	$0.00	$0.00	Disclosure SEC source: 0001337252-26-000001 · form4-03122026_080314.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,004 Underlying: Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:41 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	6,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001337252-26-000001 · form4-03122026_080314.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
November 18, 2025 Filed Nov 20, 2025 23:50 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	6,107	$0.00	$0.00	Disclosure SEC source: 0001337252-25-000004 · form4-11202025_111125.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,111 Underlying: Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. Read SEC document
November 18, 2025 Filed Nov 20, 2025 23:50 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	6,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001337252-25-000004 · form4-11202025_111125.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
August 18, 2025 Filed Aug 20, 2025 21:41 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionRestricted Stock Units · Derivative	4,071	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022516 · form4-08202025_090818.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,218 Underlying: Common Stock · 4,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. Read SEC document
August 18, 2025 Filed Aug 20, 2025 21:41 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	Exercise / conversionCommon Stock	4,071	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-022516 · form4-08202025_090818.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantDirector Stock Option (right to buy) · Derivative	39,062	$0.00 Strike: $3.07	$0.00	Disclosure SEC source: 0001415889-25-017868 · form4-06202025_080655.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 39,062 shares Expires 2035-06-17 F3 · derivative.exercise_date: 1/36 of the total shares subject to the option shall vest monthly over 3 years following the grant date of June 18, 2025. Read SEC document
June 18, 2025 Filed Jun 20, 2025 20:31 UTC	Cytek Biosciences, Inc. CTKB · Entity 5345	GrantRestricted Stock Units · Derivative	73,289	$0.00	$0.00	Disclosure SEC source: 0001415889-25-017868 · form4-06202025_080655.xml · derivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,289 Underlying: Common Stock · 73,289 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	394,000	$4.81 Strike: $4.44	$1,895,140.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 14 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 394,000 shares Expires 2031-01-19 F11 · price: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F11 · derivative.exercise_date: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	300,000	$0.00 Strike: $9.84	$0.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 13 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2030-01-16 F10 · price: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. F10 · derivative.exercise_date: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	400,000	$0.00 Strike: $9.91	$0.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 12 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2029-01-31 F9 · price: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. F9 · derivative.exercise_date: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	175,000	$0.50 Strike: $8.75	$87,500.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 11 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2028-01-22 F8 · price: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F8 · derivative.exercise_date: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	175,000	$2.85 Strike: $6.40	$498,750.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 10 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2027-01-23 F7 · price: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F7 · derivative.exercise_date: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	197,771	$5.80 Strike: $3.45	$1,147,071.80	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 9 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197,771 shares Expires 2026-01-08 F6 · price: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F6 · derivative.exercise_date: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	197,771	$2.79 Strike: $6.46	$551,781.09	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 8 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 197,771 shares Expires 2025-02-05 F5 · price: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F5 · derivative.exercise_date: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	350,000	$0.00 Strike: $16.52	$0.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 7 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2024-02-04 F4 · price: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration. F4 · derivative.exercise_date: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerStock Option (right to buy) · Derivative	400,000	$8.89 Strike: $0.36	$3,556,000.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · derivative · entry 6 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2023-02-04 F3 · price: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. F3 · derivative.exercise_date: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerCommon Stock	2,000	$9.25	$18,500.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · nonDerivative · entry 5 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By reporting person as custodian for daughter Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerCommon Stock	2,000	$9.25	$18,500.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · nonDerivative · entry 4 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By reporting person as custodian for son Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerCommon Stock	2,000	$9.25	$18,500.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · nonDerivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By reporting person as custodian for daughter Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerCommon Stock	2,000	$9.25	$18,500.00	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By reporting person as custodian for son Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. Read SEC document
August 27, 2021 Filed Aug 31, 2021 01:46 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Disposition to issuerCommon Stock	1,709,271	$9.25	$15,810,756.75	Disclosure SEC source: 0001250853-21-000092 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents 1,709,271 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share. Certain of these securities were restricted stock units ("RSUs") that represented the reporting person's right to receive the Kindred Biosciences, Inc.'s common stock. Pursuant to the Merger Agreement, the RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive a cash payment of $9.25 per share, subject to any required withholding of taxes. Read SEC document
August 02, 2021 Filed Aug 4, 2021 19:00 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	SaleCommon Stock	40,000	$9.21	$368,240.00	Disclosure SEC source: 0001250853-21-000081 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534,271 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 22, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.215, inclusive. The reporting person undertakes to provide to Kindred Biosciences, Inc., any security holder of Kindred Biosciences, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document
July 22, 2021 Filed Aug 4, 2021 19:00 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	GiftCommon Stock	320,000	$0.00	$0.00	Disclosure SEC source: 0001250853-21-000081 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,574,271 Read SEC document
July 02, 2021 Filed Jul 7, 2021 16:02 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	SaleCommon Stock	40,000	$9.18	$367,080.00	Disclosure SEC source: 0001250853-21-000071 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,271 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 22, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.17 to $9.19, inclusive. The reporting person undertakes to provide to Kindred Biosciences, Inc., any security holder of Kindred Biosciences, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document
June 16, 2021 Filed Jun 18, 2021 01:30 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	SaleCommon Stock	40,000	$9.18	$367,268.00	Disclosure SEC source: 0001250853-21-000066 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,934,271 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 22, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.165 to $9.19, inclusive. The reporting person undertakes to provide to Kindred Biosciences, Inc., any security holder of Kindred Biosciences, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document
February 01, 2021 Filed Feb 3, 2021 20:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionRestricted Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001250853-21-000024 · primary_doc.xml · derivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: In February 2019, the reporting person was granted 50,000 restricted stock units that vest in four equal annual installments. F3 · derivative.expiration_date: In February 2019, the reporting person was granted 50,000 restricted stock units that vest in four equal annual installments. Read SEC document
February 01, 2021 Filed Feb 3, 2021 20:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	6,582	$5.00	$32,910.00	Disclosure SEC source: 0001250853-21-000024 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974,271 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
February 01, 2021 Filed Feb 3, 2021 20:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionCommon Stock	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001250853-21-000024 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 23, 2021 Filed Jan 27, 2021 01:36 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	13,163	$4.93	$64,893.59	Disclosure SEC source: 0001250853-21-000021 · primary_doc.xml · nonDerivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,968,353 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
January 22, 2021 Filed Jan 27, 2021 01:36 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00	$0.00	Disclosure SEC source: 0001250853-21-000021 · primary_doc.xml · derivative · entry 4 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 22, 2021 Filed Jan 27, 2021 01:36 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	19,744	$4.93	$97,337.92	Disclosure SEC source: 0001250853-21-000021 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,981,516 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
January 22, 2021 Filed Jan 27, 2021 01:36 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionCommon Stock	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001250853-21-000021 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 20, 2021 Filed Jan 21, 2021 00:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	GrantStock Option (right to buy) · Derivative	394,000	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001250853-21-000014 · primary_doc.xml · derivative · entry 4 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,000 Underlying: Common Stock · 394,000 shares Expires 2031-01-19 F4 · derivative.exercise_date: The option will vest as to 25% after one year following the date of grant, and the remainder will vest in 36 equal monthly installments over the following three years. Read SEC document
January 17, 2021 Filed Jan 21, 2021 00:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00	$0.00	Disclosure SEC source: 0001250853-21-000014 · primary_doc.xml · derivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 17, 2020, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 17, 2020, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 17, 2021 Filed Jan 21, 2021 00:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	21,128	$4.95	$104,583.60	Disclosure SEC source: 0001250853-21-000014 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963,760 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
January 17, 2021 Filed Jan 21, 2021 00:20 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionCommon Stock	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001250853-21-000014 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,984,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 11, 2020 Filed Feb 13, 2020 21:28 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionRestricted Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001250853-20-000041 · primary_doc.xml · derivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: In February 2019, the reporting person was granted 50,000 restricted stock units that vest in four equal annual installments. F3 · derivative.expiration_date: In February 2019, the reporting person was granted 50,000 restricted stock units that vest in four equal annual installments. Read SEC document
February 11, 2020 Filed Feb 13, 2020 21:28 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	4,317	$9.22	$39,802.74	Disclosure SEC source: 0001250853-20-000041 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,947,388 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
February 11, 2020 Filed Feb 13, 2020 21:28 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionCommon Stock	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001250853-20-000041 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 23, 2020 Filed Jan 25, 2020 00:26 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	8,645	$9.66	$83,510.70	Disclosure SEC source: 0001250853-20-000037 · primary_doc.xml · nonDerivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,205 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
January 22, 2020 Filed Jan 25, 2020 00:26 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionRestricted Stock Units · Derivative	37,500	$0.00	$0.00	Disclosure SEC source: 0001250853-20-000037 · primary_doc.xml · derivative · entry 4 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 22, 2020 Filed Jan 25, 2020 00:26 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Tax withholdingCommon Stock	11,607	$9.88	$114,677.16	Disclosure SEC source: 0001250853-20-000037 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,947,850 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document
January 22, 2020 Filed Jan 25, 2020 00:26 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	Exercise / conversionCommon Stock	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001250853-20-000037 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,959,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.